<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01017770</url>
  </required_header>
  <id_info>
    <org_study_id>ACTEffectiveness</org_study_id>
    <nct_id>NCT01017770</nct_id>
  </id_info>
  <brief_title>Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso</brief_title>
  <acronym>ACTE</acronym>
  <official_title>Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Muraz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Muraz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several countries in Africa have changed their first-line treatment for uncomplicated malaria
      to an ACT. Burkina Faso has changed its policy to Artemether-Lumefantrine (AL) and
      Artesunate-Amodiaquine (AQ+AS). However, such choice has been done without knowing the local
      effectiveness of these drugs when they are given to patients in real life conditions, without
      direct observation of the drug administration. Thus, this study aims at investigating the
      effectiveness of AQ+AS and AL, when given to children with uncomplicated malaria in Burkina
      Faso.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polymerase chain reaction (PCR) adjusted treatment failure</measure>
    <time_frame>Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment failure up to day 42 (PCR adjusted and unadjusted)</measure>
    <time_frame>Day 42</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gametocytes (prevalence and density)</measure>
    <time_frame>At day 7, 14, 21, 28, 35 and 42 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb changes</measure>
    <time_frame>Day 35</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Uncomplicated P. Falciparum Malaria in Children</condition>
  <arm_group>
    <arm_group_label>Artemether -lumefantrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Treatment of malaria with Artemether-lumefantrine (AL), according to one of the two options given by national protocol in Burkina Faso</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artesunate-amodiaquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of malaria with Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate-amodiaquine</intervention_name>
    <description>Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)</description>
    <arm_group_label>Artesunate-amodiaquine</arm_group_label>
    <other_name>ASAQ, Coarsucam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artemether-lumefantrine</intervention_name>
    <description>Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing &gt; 35 kg.</description>
    <arm_group_label>Artemether -lumefantrine</arm_group_label>
    <other_name>AL, Coartem(R), Riamet(R)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Weight &gt; 5 kg;

          -  Monoinfection with P. falciparum and a parasitaemia of 2,000-200,000 parasites /µl;

          -  Fever (axillary temperature ≥37.5 °C) or history of fever in the preceding 24 hours;

          -  Haemoglobin value above 5.0 g/dl;

          -  Absence of febrile conditions caused by diseases other than malaria.

        Exclusion Criteria:

          -  Danger signs: not able to drink or breast-feed, vomiting (&gt; twice in 24hours), recent
             history of convulsions (&gt;1 in 24h), unconscious state, unable to sit or stand;

          -  Signs of severe malaria (WHO 2000);

          -  Mixed malaria infection;

          -  Severe malnutrition;

          -  Other underlying diseases (cardiac, renal, hepatic diseases);

          -  History of allergy to study drugs;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nanoro</name>
      <address>
        <city>Nanoro</city>
        <state>Boulkiemdé</state>
        <zip>115</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanoro</name>
      <address>
        <city>Nanoro</city>
        <state>Boulkiemdé</state>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRSS-DRO/Centre Muraz</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <state>Bp 545</state>
        <zip>01</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tinto Halidou</name>
      <address>
        <city>Bobo-Dioulasso</city>
        <state>Houet</state>
        <zip>01</zip>
        <country>Burkina Faso</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Burkina Faso</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>July 29, 2015</last_update_submitted>
  <last_update_submitted_qc>July 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Muraz</investigator_affiliation>
    <investigator_full_name>Tinto Halidou</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <keyword>Uncomplicated malaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
    <mesh_term>Malaria, Falciparum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Lumefantrine</mesh_term>
    <mesh_term>Artemether</mesh_term>
    <mesh_term>Artemether-lumefantrine combination</mesh_term>
    <mesh_term>Amodiaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

